Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers

Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor radionuclide therapy (PRRT), toxicity has been observed due to high doses delivered...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Onofrio, Alice, Silva, Francisco, Gano, Lurdes, Raposinho, Paula, Fernandes, Célia, Sikora, Arkadiusz, Wyczółkowska, Monika, Mikołajczak, Renata, Garnuszek, Piotr, Paulo, António
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785946/
https://www.ncbi.nlm.nih.gov/pubmed/36559063
http://dx.doi.org/10.3390/pharmaceutics14122569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785946/
https://www.ncbi.nlm.nih.gov/pubmed/36559063
http://dx.doi.org/10.3390/pharmaceutics14122569

Ejemplares similares